Cantor Fitzgerald analyst Sarah James raised the firm’s price target on LifeMD to $11 from $9 and keeps an Overweight rating on the shares. LifeMD reported a strong quarter with a sizable adjusted EBITDA beat, and Cantor views LifeMD as uniquely positioned for a young high-growth healthcare services company as they are cash flow positive with positive and expanding EBITDA margins, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LFMD:
- LifeMD Reports Fourth Quarter 2023 Results
- Lifemd, Inc. (LFMD) Q4 Earnings Cheat Sheet
- Medifast price target lowered to $40 from $67 at DA Davidson
- LifeMD to Participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference
